← All trials
NCT02736552
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2016
- Primary completion
- Mar 1, 2018
- Completion date
- Mar 1, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 680
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Sun Yat-Sen UniversityReponsible party - principal investigator
- Anhui Medical UniversityCollaborator
- Guangdong Provincial Hospital of Traditional Chinese MedicineCollaborator
- Anqing Municipal HospitalCollaborator
- Yuebei People's HospitalCollaborator
- Zhejiang UniversityCollaborator
- Wannan Medical CollegeCollaborator
- Anhui College of Traditional Chinese MedicineCollaborator
- Shenzhen UniversityCollaborator
- Guangdong Pharmaceutical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.